Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Developments research found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://mitche542hjj3.blogsidea.com/profile